Experimental weight loss drug retatrutide shows dramatic weight loss in clinical trial Amid the growing demand for GLP-1 medications for weight loss, a new experimental drug, retatrutide, stands out, according to new clinical trial results released on Thursday
The goal is to understand why inflammatory signaling is elevated and whether modifiable drivers are present: visceral fat, periodontal disease, poor sleep, alcohol, insulin resistance, autoimmune activity, environmental exposure, chronic infection, or unresolved cardiometabolic risk
Pallo, Kristine Faerch, Anette P
We believe that starts with education, to help all of us understand our always-changing bodies and health needs
Same for large meals
Originally approved for type 2 diabetes, GLP-1 medications surged in popularity for another reason: weight loss